We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,242

Proving Utility, Demonstrating Value: How to Align the Moving Parts in Personalized Medicine Reimbursement
  • Foley & Lardner LLP
  • USA
  • April 20 2017

Of the many business, operational, legal, regulatory and clinical obstacles standing in the way of widespread delivery of personalized medicine, the


Angiomax Patents Limited To Example
  • Foley & Lardner LLP
  • USA
  • April 18 2017

In The Medicines Co. v. Mylan, Inc., the Federal Circuit construed composition claims of two Angiomax patents as requiring the recited “batches” to


Forget Bigger Data - Personalized Medicine Needs Smarter Data to Reach its Full Potential
  • Foley & Lardner LLP
  • USA
  • April 18 2017

The advent of big data has helped enable the growth of personalized medicine. But if machine learning and analytics are to truly help transform


Prescribing Controlled Substances Without an In-Person Exam: The Practice of Telemedicine Under the Ryan Haight Act
  • Foley & Lardner LLP
  • USA
  • April 17 2017

As providers are becoming more comfortable with delivering care via telemedicine Technologies, many of them are looking to explore services other


Trump Administration Issues Guidance On The “Two-for-One” Reduction In Regulations
  • Foley & Lardner LLP
  • USA
  • April 12 2017

Last week, the Trump Administration issued guidance on Executive Order 13771, “Reducing Regulation and Controlling Regulatory Costs.” The guidance


Telemedicine Prescribing and Controlled Substances Laws
  • Foley & Lardner LLP
  • USA
  • April 3 2017

As providers become more comfortable with delivering care via telemedicine, telehealth, and digital health Technologies, some are exploring services


Guidebook: Cybersecurity in the Pharma, Biotech, and Medical Devices Industries
  • Foley & Lardner LLP
  • Global, USA
  • April 3 2017

As a life sciences or medical device company, it is mission critical to protect lab books, drug and clinical test data, product Formula


New Resources for Telehealth Chronic Care Management (CCM) Rules
  • Foley & Lardner LLP
  • USA
  • March 27 2017

More good news for hospitals, health care providers, and entrepreneurs interested in telehealth and Chronic Care Management (CCM). CMS just recently


Seven Key Questions in Understanding the Current Regulatory State of HCTPs
  • Foley & Lardner LLP
  • USA
  • March 20 2017

Despite regulations, litigation, and significant draft guidance, the future of regulation of HCTPs remains up in the air. Learn what you need to


HHS and Medicare Asked to Expand Coverage for Genetic Tests
  • Foley & Lardner LLP
  • USA
  • March 16 2017

Fifteen members of Congress have asked the Department of Health and Human Services (HHS) and the Medicare Payment Advisory Commission (Medicare) to